EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Real-world data on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)-directed therapy in patients with peritoneal metastases; Third annual report from the ISSPP PIPAC database

Magnus Skov Jørgensen, Pernille Schjødt Hansen, Claus W. Fristrup, Martin Hübner, Jimmy So, Anne-Cecile Ezanno, Peter Hewett, Miguel Ruiz-Marin, Günther A. Rezniczek, Özgül Düzgün, Marc Pocard, Francesco Casella, Laura Lay, Marisa Aral, Tarkan Jäger, Felix Laminger, Oliver Glehen, Claire-Angéline Goutard, Laurent Villeneuve, Andrea Di Giorgio, Michael Bau Mortensen

Pleura and Peritoneum · 2025-09-24 · 10 (3) · 119-128

DOI: 10.1515/pp-2025-0013 ↗
AbstractBibliografische Angaben

Abstract

Abstract Objectives In 2020, the International Society for the Study of the Pleura and Peritoneum (ISSPP) launched a database monitoring real-world data on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)-directed therapy in patients with peritoneal metastases (PM). This study covers data from the third annual report on the ISSPP PIPAC database. Methods Systematic analysis of all data reported to the ISSPP PIPAC database between June 15th, 2020, and November 1st, 2024. We hypothesize that ISSPP PIPAC data align with existing literature. Results Seventeen PIPAC centers reported 3224 PIPAC treatments in 1126 patients with PM (median number of treatments 2, range 1–33). The median peritoneal cancer index (PCI) at PIPAC 1 was 19 and remained unchanged during subsequent treatments. The number of patients with >500 mL ascites significantly decreased from the first three PIPAC treatments to PIPAC 4+ (p2). Conclusions This study from the ISSPP PIPAC database provides substantial real-world data demonstrating the feasibility, safety, and potential effect of PIPAC-directed therapy in patients with PM.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →